In Brief: Roche/Organon Teknika
This article was originally published in The Gray Sheet
Roche/Organon Teknika: Ink worldwide settlement agreement to end patent litigation pending in several countries including the U.S. related to nucleic acid amplification technology. Hoffmann-La Roche first brought suit against Teknika in 1995 in The Netherlands alleging that Teknika's NASBA RNA transcription-based gene amplification system infringed Roche patents covering its PCR polymerase chain reaction gene amplification technology. Since the initial suit was filed, Dutch and German courts have ruled in Teknika's favor in the disputes ("The Gray Sheet" Sept. 16, 1996, In Brief). Terms of the settlement are not being disclosed...
You may also be interested in...
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
Months of pandemic-induced disruption to health care systems and freedom of movement undoubtedly carries a cost. For the biopharmaceutical industry, this can be mitigated by its essential role in providing therapeutic interventions and leading the fightback via prophylactic vaccines. This softens the blow somewhat, certainly compared to other industries that are fully exposed to COVID-19 headwinds.
RSNA is the next major global medtech event to be run under a virtual format this fall. Under COVID-19, the major medtechs are finding different ways to demonstrate value, as Royal Philips explains.